When epilepsy with myoclonic absences is diagnosed in a patient younger than 16 years, age is a defining factor in determining which treatment pathway applies. This first-line protocol is specific to the pediatric age group.
This protocol is indicated for children under 16 years of age with epilepsy with myoclonic absences. Pediatric age is the criterion that places patients in this specific treatment pathway.
Management begins with monotherapy using a level A (highest-evidence) first-line agent. The complete protocol specifies which agents qualify, how the choice is structured, and the full therapeutic sequence — see the regimen below.